Literature DB >> 10213538

Myotonic dystrophy and progressive cognitive decline: a common condition or two separate problems?

B A Wilson1, H Balleny, K Patterson, J R Hodges.   

Abstract

We report the case of NG, a 43-year old woman with myotonic dystrophy (MYD) who has shown a slow decline in both motor and cognitive abilities since her referral to us at age 32. MYD is an autosomal dominant disorder characterised by weakening and wasting of the muscles together with impaired muscle relaxation. Cognitive abilities are usually little affected in the adult onset form, although there is a high risk of cognitive impairment in those with childhood onset. Cognitive decline is also typically associated with maternal inheritance. NG, who was diagnosed with MYD at the age of 18, inherited it from her father. We report the decline in NG's cognitive abilities over 11 years of longitudinal assessment, and consider whether she is an atypical MYD patient or whether the MYD and cognitive decline are attributable to two separate pathological processes.

Entities:  

Mesh:

Year:  1999        PMID: 10213538     DOI: 10.1016/s0010-9452(08)70789-5

Source DB:  PubMed          Journal:  Cortex        ISSN: 0010-9452            Impact factor:   4.027


  3 in total

Review 1.  Myotonic dystrophy: RNA pathogenesis comes into focus.

Authors:  Laura P W Ranum; John W Day
Journal:  Am J Hum Genet       Date:  2004-04-02       Impact factor: 11.025

2.  Cognitive deficits and CTG repeat expansion size in classical myotonic dystrophy type 1 (DM1).

Authors:  Stefan Winblad; Christopher Lindberg; Stefan Hansen
Journal:  Behav Brain Funct       Date:  2006-05-15       Impact factor: 3.759

3.  Disease awareness in myotonic dystrophy type 1: an observational cross-sectional study.

Authors:  Sigrid Baldanzi; Francesca Bevilacqua; Rita Lorio; Leda Volpi; Costanza Simoncini; Antonio Petrucci; Mirco Cosottini; Gabriele Massimetti; Gloria Tognoni; Giulia Ricci; Corrado Angelini; Gabriele Siciliano
Journal:  Orphanet J Rare Dis       Date:  2016-04-04       Impact factor: 4.123

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.